Initial Treatment Approach for Sjögren Antibody-Positive Patients

Diagnostic Workup and Treatment Algorithm

The American College of Rheumatology recommends obtaining baseline chest radiography in all antibody-positive patients to identify subclinical interstitial lung disease, which occurs frequently in this population 2
The European League Against Rheumatism (EULAR) suggests considering baseline complete pulmonary function tests (spirometry, DLCO, and lung volumes by body plethysmography) even without respiratory symptoms, as these aid in identifying subclinical disease and provide comparison for future monitoring 3, 4
For symptomatic patients, the initial treatment approach should include immediate topical therapies for sicca symptoms, with systemic immunosuppression reserved only for those with active systemic disease as measured by ESSDAI scoring 1, 2
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) should be used to quantify disease severity and determine treatment intensity, stratifying patients into low (ESSDAI 1-4), moderate (ESSDAI 5-13), or high disease activity categories 1, 2

For ocular dryness management, artificial tears containing methylcellulose or hyaluronate should be started at least twice daily, increasing frequency based on symptoms, and preservative-free formulations should be used if requiring four or more applications per day 1
For oral dryness management, saliva substitutes should be initiated, and oral muscarinic agonists (pilocarpine or cevimeline) should be considered for moderate to severe xerostomia 1, 7

For moderate to severe systemic disease (ESSDAI 5-13 or higher), systemic immunosuppression is indicated, and glucocorticoids should be initiated at the minimum effective dose, with immunosuppressive agents (azathioprine, mycophenolate, or methotrexate) added as glucocorticoid-sparing agents 1, 2
For interstitial lung disease specifically, first-line treatment is mycophenolate mofetil or azathioprine plus moderate-dose corticosteroids, and nintedanib should be added as second-line maintenance for progressive fibrotic ILD 2

Pulmonary function tests should be repeated every 6-12 months in patients with baseline abnormalities or respiratory symptoms to track disease trajectory, and ESSDAI should be reassessed at regular intervals to guide treatment adjustments 1, 2
Lymphoma surveillance should be performed at each visit, monitoring for lymphadenopathy, fevers, and night sweats, as lymphoma develops in 2-5% of patients 1, 2